SCHEMBL24252836

SCHEMBL24252836

CC(C)NC(=O)COc1ccc(Cl)cc1Br

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.75
NPC1 O15118 5/20 0.62
LMNA P02545 4/20 0.61
RAB9A P51151 3/20 0.61
HPGD P15428 3/20 0.61
GAA P10253 1/20 0.60
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
KMT2A Q03164 1/20 0.58
MAPT P10636 3/20 0.57
NR2F2 P24468 1/20 0.56
NLRP1 Q9C000 1/20 0.55
KDM4E B2RXH2 1/20 0.55
RECQL P46063 1/20 0.54
PKM P14618 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451475 1.00 SMN1; SMN2 (0.75) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL24740256 0.86 SMN1; SMN2 (1.00) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL2560314 0.81 SMN1; SMN2 (0.71) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL15613286 0.81 SMN1; SMN2 (0.59) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL5007025 0.80 GAA (0.62) SMN1; SMN2NPC1LMNARAB9AGAA
SCHEMBL1369311 0.77 TDP1 (0.70) NPC1LMNARAB9AGAAALDH1A1
SCHEMBL23273087 0.77 GAA (0.59) SMN1; SMN2NPC1LMNARAB9AGAA
SCHEMBL8248742 0.76 SMN1; SMN2 (0.64) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL27300755 0.76 SMN1; SMN2 (0.77) SMN1; SMN2NPC1LMNARAB9AHPGD
SCHEMBL21197878 0.75 SMN1; SMN2 (0.61) SMN1; SMN2NPC1LMNARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SMN1; SMN2 782/4885NPC1 460/4885LMNA 3767/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 SMN1; SMN2 782/4885NPC1 460/4885LMNA 3767/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 SMN1; SMN2 782/4885NPC1 460/4885LMNA 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.